New hope for Tough-to-Treat ovarian cancer: first patients sought for experimental injection
NCT ID NCT07462468
Summary
This is a first-in-human study to test the safety and find the right dose of an experimental drug called WSK-IM02 for women with recurrent ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll up to 36 participants who will receive the drug via injection into the abdomen. The main goals are to see how well the drug is tolerated and to gather early signs of whether it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.